securities star news, on April 22 Huaxi biology (688363) rose 8.10 percent to close at 57.91 yuan, with a turnover rate of 2.19 percent, with a turnover of 43400 hands and a turnover of 0.247 billion yuan. The unit is a hot unit for ophthalmology, large consumption, medical devices, synthetic biology, cosmetics, medical beauty concept. In terms of capital flow data on April 22, the net outflow of main funds was 20.9716 million yuan, accounting for 8.49 per cent of the total turnover, the net outflow of hot money was 27.5128 million yuan, accounting for 11.13 per cent of the total turnover, and the net inflow of retail funds was 48.4844 million yuan, accounting for 19.62 per cent of the total turnover. In the last 5 days, the net outflow of financing was 10.3357 million, the balance of financing decreased, and the net outflow of margin securities was 158100, and the balance of margin securities decreased.

Please refer to the following table for the public offering funds of Heavy Warehouse Huaxi Bio:

The stock has been rated by 7 institutions in the last 90 days, with 5 buying ratings and 2 overweight ratings; the average institutional target price in the past 90 days is 97.21.

According to the 2024 Fund Q1 Quarterly Report Public Fund Heavy Stock Data, there is a total of 1 public fund with a heavy position in the stock, of which the largest number of public funds are the Harvest SSE Biopharmaceutical ETF. The Castrol SSE Biopharmaceutical ETF is currently 0.083 billion yuan in size, with the latest net value 0.8117 (April 19), down 1.72 per cent from the previous trading day. The current fund manager of the public fund is Wang Zihan. Wang Zihan's fund products include: Castrol Shanghai and Shenzhen 300 Dividend Low Volatility ETF Link A, managed from September 9, 2021 to date, with a period yield of 24.15; Castrol Hang Seng Technology ETF(QDII), managed from September 9, 2021 to date, with a period yield of -48.84%; Castrol Shanghai and Shenzhen 300 Dividend Low Volatility ETF, managed from September 9, 2021 to date, with a period yield of 26.69; Castrol Pharmaceutical Health 100ETF, management time is September 9, 2021 to date, with a period yield of -38.68%.

The top ten heavyweight stocks of the Harvest SSE Biopharmaceutical ETF are as follows: